Inhibition of γ-Secretase Leads to an Increase in Presenilin-1

γ-Secretase inhibitors (GSIs) are potential therapeutic agents for Alzheimer’s disease (AD); however, trials have proven disappointing. We addressed the possibility that γ-secretase inhibition can provoke a rebound effect, elevating the levels of the catalytic γ-secretase subunit, presenilin-1 (PS1)...

Descripción completa

Detalles Bibliográficos
Autores principales: Sogorb-Esteve, Aitana, García-Ayllón, María-Salud, Llansola, Marta, Felipo, Vicente, Blennow, Kaj, Sáez-Valero, Javier
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2017
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5948247/
https://www.ncbi.nlm.nih.gov/pubmed/28815510
http://dx.doi.org/10.1007/s12035-017-0705-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5948247/
https://www.ncbi.nlm.nih.gov/pubmed/28815510
http://dx.doi.org/10.1007/s12035-017-0705-1

Ejemplares similares